The latest price target for Telix Pharmaceuticals (NASDAQ:TLX) was reported by Wedbush on April 13, 2026. The analyst firm set a price target for $22.00 expecting TLX to rise to within 12 months (a possible 109.52% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Telix Pharmaceuticals (NASDAQ:TLX) was provided by Wedbush, and Telix Pharmaceuticals reiterated their outperform rating.

There is no last upgrade for Telix Pharmaceuticals

The last downgrade for Telix Pharmaceuticals Ltd happened on August 28, 2025 when JP Morgan changed their price target from N/A to N/A for Telix Pharmaceuticals Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Telix Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Telix Pharmaceuticals was filed on April 13, 2026 so you should expect the next rating to be made available sometime around April 13, 2027.

While ratings are subjective and will change, the latest Telix Pharmaceuticals (TLX) rating was a reiterated with a price target of $22.00 to $22.00. The current price Telix Pharmaceuticals (TLX) is trading at is $10.50, which is out of the analyst’s predicted range.